Etienne M. Sokal is at the Université catholique de Louvain, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, B-1200 Brussels, Belgium.
Checking for direct PDF access through Ovid
In a new report, adolescents with genotype 2 or 3 HCV infection who were given sofosbuvir and ribavirin showed a near 100% sustained virologic response. This study is the beginning of a new wave of treatments for paediatric HCV infection, forming part of a global strategy to eradicate viral hepatitis.Refers to Wirth, S. et al. Sofosbuvir and ribavirin in adolescents 12 to 17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatologyhttp://dx.doi.org/10.1002/hep.29278 (2017)